Constitutive Expression and Involvement of Cyclooxygenase-2 in Human Megakaryocytopoiesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 3, 2004, Pages 607-612

  Tanaka, Nobuhito ^a   Sato, Takahiro ^a   Fujita, Hiroshi ^a   Morita, Ikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 2; Megakaryocytopoiesis; Platelets; Thromboxane A2

Indexed keywords

CD34 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN RECEPTOR; INDOMETACIN; MESSENGER RNA; MOFEZOLAC; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROPIDIUM IODIDE; STEM CELL FACTOR; THROMBOPOIETIN; THROMBOXANE A2;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIQUID CULTURE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOSIS; UMBILICAL CORD BLOOD;

CELL DIFFERENTIATION; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME INDUCTION; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT, NEWBORN; ISOENZYMES; ISOXAZOLES; MEGAKARYOCYTES; MEMBRANE PROTEINS; NITROBENZENES; PLATELET COUNT; PLURIPOTENT STEM CELLS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; STEM CELL FACTOR; SULFONAMIDES; THROMBOPOIESIS; THROMBOPOIETIN; THROMBOXANE A2;

EID: 1542343985     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000117181.68309.10     Document Type: Article

References (46)

1. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
2. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99:7634-7639.
3. Gewirtz AM. Megakaryocytopoiesis: the state of the art. Thromb Haemost. 1995;74:204-209.
4. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996;88:1284-1296.
5. Lepage A, Leboeuf M, Cazenave JP, de la Salle C, Lanza F, Uzan G. The alpha(IIb)beta(3) integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. Blood. 2000;96:4169-4177.
6. Zucker-Franklin D, Petursson S. Thrombocytopoiesis-analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes. J Cell Biol. 1984;99:390-402.
7. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood. 1996;87:4544-4551.
8. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85:1719-1726.
9. Tabilio A, Rosa JP, Testa U, Kieffer N, Nurden AT, Del Canizo MC, Breton-Gorius J, Vainchenker W. Expression of platelet membrane glycoproteins and alpha-granule proteins by a human erythroleukemia cell line (HEL). EMBO J. 1984;3:453-459.
10. Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R, Handin RI. Characterization of a new megakaryocytic cell line: the Dami cell. Blood. 1988;72:1968-1977.
11. Sato T, Fuse A, Eguchi M, Hayashi Y, Ryo R, Adachi M, Kishimoto Y, Teramura M, Mizoguchi H, Shima Y. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. Br J Haematol. 1989;72:184-190.
12. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, Saito H. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985;66: 1384-1392.
13. Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H, Yawata Y. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival, Cancer Res. 1991; 51:341-348.
14. Avanzi, G. C., Lista, P., Giovinazzo, B., Miniero, R., Saglio, G., Benetton, G., Coda, R., Cattoretti, G., and Pegoraro, L. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 1988;69:359-366.
15. Sledge GW Jr., Glant M, Jansen J, Heerema NA, Roth BJ, Goheen M, Hoffman R. Establishment in long term culture of megakaryocytic leukemia cells (EST-IU) from the marrow of a patient with leukemia and a mediastinal germ cell neoplasm. Cancer Res. 1986;46:2155-2159.
16. Takeuchi S, Sugito S, Uemura Y, Miyagi T, Kubonishi I, Taguchi H, Enzan H, Ohtsuki Y, Miyoshi I. Acute megakaryoblastic leukemia: establishment of a new cell line (MKPL-1) in vitro and in vivo. Leukemia. 1992;6:588-594.
17. Seigneurin D, Champelovier P, Mouchiroud G, Berthier R, Leroux D, Prenant M, McGregor J, Starck J, Morle F, Micouin C. Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics. Exp Hematol. 1987;15:822-832.
18. Sato T, Ono M, Fujita H, Tanaka N, Tomiyama J, Sakamoto Y, Takano Y, Murota S, Morita I. Development of a liquid culture system for megakaryocyte terminal differentiation: Fibrinogen promotes megakaryocytopoiesis but not thrombopoiesis. Br J Haematol 2003;121:315-323.
19. Kaneki H, Takasugi I, Fujieda M, Kiriu M, Mizuochi, S, Ide, H. Prostaglandin E2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. J Cell Biochem. 1999;73:36-48.
20. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
21. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, Fitzgerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999;103:1469-1477.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
23. Tsubouchi Y, Sano H, Yamada R, Hashiramoto A, Kohno M, Kusaka Y, Kondo M. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Eur J Pharmacol. 2000;395:255-263.
24. Slater DM, Dennes WJB, Campa JS, Poston L, Bennett PR. Expression of cyclo-oxygenase types-1 and -2 in human myometrium throughout pregnancy. Mol Hum Reprod. 1999;5:880-884.
25. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest. 1996;97:949-956.
26. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994;47:55-59.
27. Kusuhara H, Fukunari A, Matsuyuki H, Okumoto T. Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid. Brain Res Mol Brain Res. 1997;52:151-156.
28. Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, Sugimura T, Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis. 2002;23:1463-1466.
29. Ueda N, Yamashita R, Yamamoto S, Ishimura K. Induction of cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim Biophys Acta. 1997;1344:103-110.
30. Matijevic-Aleksic N, Sanduja SK, Wang LH, Wu KK. Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta. 1995;1269:167-175.
31. Weber AA, Zimmermann KC, Kirchrath JM, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.
32. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993;11: 371-386.
33. Harris RC, McKanna JA, Akai Y, Jacobson HR, DuBois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
34. Walenga RW, Koster M, Coroneos E, Butcher S, Dwivedi R, Statt C. Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in hum an tracheal epithelial cells in vitro. Prostaglandins. 1996;52:341-359.
35. Sorli CH, Zhang HJ, Armstrong MB, Rajotte RV, Maclouf J, Robertson R P. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U S A. 1998;95:1788-1793.
36. Gallois C, Habib A, Tao J, Moulin S, Maclouf J, Mallat A, Lotersztajn S. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem. 1998;273:23183-23190.
37. Lorenz M, Slaughter HS, Wescott DM, Carter SI, Schnyder B, Dinchuk JE, Car BD. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol. 1999;27: 1494-1502.
38. Vitrat N, Letestu R, Masse A, Lazar V, Vainchenker W, Debili N. Thromboxane synthase has the same pattern of expression as platelet specific glycoproteins during human megakaryocyte differentiation. Thromb Haemost. 2000;83:759-768.
39. Dube JN, Drouin J, Aminian M, Plant MH, Laneuville O. Characterization of a partial prostaglandin endoperoxide H synthase-1 deficiency in a patient with a bleeding disorder. Br J Haematol. 2001;113:878-888.
40. Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002;105:387-392.
41. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002;100: 917-924.
42. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
43. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997;96:1109-1116.
44. Shitashige M, Morita I, Murota S. Different substrate utilization between prostaglandin endoperoxide H synthase-1 and -2 in NIH3T3 fibroblasts. Biochim Biophys Acta. 1998;1389:57-66.
45. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
46. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.